[PDF] snmjournals.orgFree from Publisher

Safety of Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Neuroendocrine Tumor Patients with Chronic Kidney Disease

S Alsadik, G Gnanasegaran, L Chen… - Journal of Nuclear …, 2022 - Soc Nuclear Med
Our purpose was to assess the efficacy and safety of 177Lu-DOTATATE in neuroendocrine
tumor patients with reduced renal function. Methods: A single-center retrospective analysis …
Save Cite Cited by 5 Related articles All 6 versions

Renal and Hematological Toxicity in Patients of Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE

SK Gupta, S Singla, C Bal - Cancer Biotherapy and …, 2012 - liebertpub.com
Purpose: Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE is an
efficient new treatment option in patients with neuroendocrine tumors (NETs), with low risk of …
Save Cite Cited by 66 Related articles All 5 versions
[PDF] researchgate.net

Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors

L Bodei, M Cremonesi, M Ferrari, M Pacifici… - European journal of …, 2008 - Springer
Purpose Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumours with 90
Y-DOTATOC and 177 Lu-DOTATATE is promising. The kidney is the critical organ and …
Save Cite Cited by 458 Related articles All 21 versions

Safety and efficacy of peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumor patients having single kidney or nonfunctional kidney

V Prasad, H Kulkarni, C Zachert, D Hoersch, R Baum - 2011 - Soc Nuclear Med
1741 Objectives To determine safety and efficacy of PRRNT in patients with a single kidney
or high grade/terminal renal insufficiency in metastasized neuroendocrine tumors. Methods …
Save Cite Cited by 3 Related articles
[PDF] snmjournals.orgFree from Publisher

177Lu-DOTATATE PRRT in patients with metastatic neuroendocrine tumor and a single functioning kidney: tolerability and effect on renal function

R Ranade, S Basu - Journal of Nuclear Medicine Technology, 2016 - Soc Nuclear Med
Our objective was to assess the renal toxicity profile of 177Lu-DOTATATE peptide receptor
radionuclide therapy (PRRT) in patients with a metastatic neuroendocrine tumor (NET) and …
Save Cite Cited by 9 Related articles All 5 versions
[PDF] ndmctsgh.edu.tw

Extended peptide receptor radionuclide therapy: evaluating nephrotoxicity and therapeutic effectiveness in neuroendocrine tumor patients receiving more than four …

RP Baum, X Fan, V Jakobsson, C Schuchardt… - European Journal of …, 2023 - Springer
Purpose Currently, the most used peptide receptor radionuclide therapy (PRRT) regimen for
neuroendocrine tumors comprises 4 treatment cycles, and there is not enough large-scale …
Save Cite Related articles All 3 versions

Monitoring kidney function in neuroendocrine tumor patients treated with 90Y-DOTATOC: associations with risk factors

AK Arveschoug, S MJ Kramer, P Iversen… - Current …, 2015 - ingentaconnect.com
Peptide receptor radionuclide therapy (PRRT) is an established treatment for progressive
neuroendocrine tumours with nephrotoxicity as the limiting factor. It is therefore important to …
Save Cite Cited by 8 Related articles All 4 versions
[HTML] springer.com

[HTML][HTML] Renal function affects absorbed dose to the kidneys and haematological toxicity during 177Lu-DOTATATE treatment

J Svensson, G Berg, B Wängberg, M Larsson… - European journal of …, 2015 - Springer
Purpose Peptide receptor radionuclide therapy (PRRT) has become an important treatment
option in the management of advanced neuroendocrine tumours. Long-lasting responses …
Save Cite Cited by 105 Related articles All 13 versions

Long-term nephrotoxicity after peptide receptor radionuclide therapy (PRRT): myth or reality?

J Zhang, H Kulkarni, A SINGH, K Niepsch… - 2019 - Soc Nuclear Med
567 Objectives: Kidneys are generally considered as the potential dose-limiting organ for
peptide receptor radionuclide therapy (PRRT) and consequently are of primary concern. The …
Save Cite Cited by 2 Related articles

177Lu-dotatate use in chronic kidney disease patients: A single center experience

S Manohar, P Kompotiatis… - Journal of Onco …, 2021 - journals.sagepub.com
Background: Peptide receptor radionuclide therapy with 177Lu-dotatate is a novel therapy
for metastatic neuroendocrine cancers. It undergoes reabsorption at the proximal tubule; …
Save Cite Cited by 3 Related articles